In brief: Agenix; Cellestis; Prima Biomed; Novogen
Thursday, 14 April, 2005
Agenix (OTC: AGXLY, ASX: AGX) subsidiary, Agen Biomedical has signed an agreement with diagnostics company Axis-Shield under which Axis-Shield will produce a new laboratory assay for deep vein thrombosis and pulmonary embolism. The Axis-Shield assay will use Agen's 3B6 D-dimer antibody, and will be incorporated into Abbott Laboratories' mmunodiagnostic analyser, AxSYM.
Cellestis' (ASX: CST) TB diagnostic Quantiferon TB Gold has been approved for sale in by the Japanese Ministry of Health, Labour and Welfare.
Prima BioMed (ASX:PRR) has appointed Dr John Sime as a non-executive director. Sime was managing director of Beecham Australia and New Zealand for nine years and later SmithKline Beecham Pharmaceuticals Australia and New Zealand. He was also chief executive of the UK BioIndustry Association for six years.
Novogen (ASX:NRT) subsidiary Glycotex has placed 10 per cent of its stock with a US professional investor for US$4 million in a private capital raising. Novogen retains 84 per cent of the company.
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
